Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167267 | 1.00 | DNM1 (0.44) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL8993961 | 1.00 | DNM1 (0.44) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7168255 | 1.00 | DNM1 (0.44) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1448412 | 0.98 | — | — | |
| SCHEMBL7166809 | 0.90 | — | — | |
| SCHEMBL1449125 | 0.79 | — | — | |
| SCHEMBL276847 | 0.75 | DNM1 (0.48) | DNM1TSHREPHX1THRBCA12 | |
| SCHEMBL276870 | 0.75 | DNM1 (0.48) | DNM1TSHREPHX1THRBCA12 | |
| SCHEMBL5469943 | 0.75 | DNM1 (0.48) | DNM1TSHREPHX1THRBCA12 | |
| SCHEMBL11667597 | 0.75 | DNM1 (0.48) | DNM1TSHREPHX1THRBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569449-B1 | For treatment of eating disorders, narcotic dependence and alcoholism. | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-05-27 | — | — | US | claimed |
| JP-9095495-A | — | — | None | — | — | JP | disclosed |
| EP-3737365-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDES | Susavion Biosciences, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019136185-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDES | SUSAVION BIOSCIENCES, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| CN-103502450-A | Methods and materials for nucleic acid manipulation | BASF SE | 2014-01-08 | — | — | CN | disclosed |
| CN-103153345-A | Amatoxin conjugates with improved linkers | HEIDELBERG PHARMA GMBH | 2013-06-12 | — | — | CN | disclosed |
| US-6569449-B1 | For treatment of eating disorders, narcotic dependence and alcoholism. | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-05-27 | — | — | US | disclosed |
| JP-H0995495-A | ANTISENSE OLIGONUCLEOTIDE, NUCLEOSIDE AND INTERMEDIATE FOR PRODUCING THE SAME, ITS SYNTHESIS, OLIGONUCLEOTIDE SYNTHESIZING UNIT AND ITS SYNTHESIS | KANSAI SHIN GIJUTSU KENKYUSHO:KK | 1997-04-08 | — | — | JP | disclosed |